Advances in ischemic stroke treatment: neuroprotective and combination therapies (Q33278117)

25 July 2017

1 reference

title

Advances in ischemic stroke treatment: neuroprotective and combination therapies (English)

1 reference

25 July 2017

Paul A Lapchak

1

0 references

author name string

Dalia M Araujo

series ordinal

2

1 reference

PubMed ID

17355216

25 July 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Emerging Drugs

25 July 2017

1 reference

25 July 2017

12

1 reference

25 July 2017

1

1 reference

25 July 2017

97-112

1 reference

Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment

25 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Penumbra is brain: no excuse not to perfuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Imaging the penumbra in acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

The ischemic penumbra: identification, evolution and treatment concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

tPA in acute ischemic stroke: United States experience and issues for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Development of thrombolytic therapy for stroke: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Argatroban tPA stroke study: study design and results in the first treated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Thrombolytic therapy for ischemic stroke--a review. Part II--Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Thrombolytic therapy with streptokinase in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Hea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

New plasminogen activators: a clinical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Thrombolysis for acute ischemic stroke: still a treatment for the few by the few.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Thrombolytic stroke therapy: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Hyperacute stroke therapy with tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

21 January 2018

Tenecteplase: a review

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

ASSENT-3: implications for future trial design and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Vampire bats yield potent clot buster for ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Production of vampire bat plasminogen activator DSPA alpha 1 in CHO and insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Production of Desmodus rotundus salivary plasminogen activator alpha1 (DSPAalpha1) in tobacco is hampered by proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Potential markers of oxidative stress in stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Tolerability of NXY-059 at higher target concentrations in patients with acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

NXY-059 for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Lost in translation: taking neuroprotection from animal models to clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Pharmacologic properties of phenyl N-tert-butylnitrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Delayed treatment with alpha-phenyl-N-tert-butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Ebselen: prospective therapy for cerebral ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Stilbazulenyl nitrone, a novel azulenyl nitrone antioxidant: improved neurological deficit and reduced contusion size after traumatic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Kinetic studies on stilbazulenyl-bis-nitrone (STAZN), a nonphenolic chain-breaking antioxidant in solution, micelles, and lipid membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinases in brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinases in cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Thrombolytics, anticoagulants, and antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Impact of low level laser irradiation on infarct size in the rat following myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Promotion of angiogenesis by low energy laser irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Neurophysiological consequences of nitroxide antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Excretion, metabolism and tissue distribution of a spin trapping agent, alpha-phenyl-N-tert-butyl-nitrone (PBN) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Low-energy laser irradiation enhances de novo protein synthesis via its effects on translation-regulatory proteins in skeletal muscle myoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Tissue plasminogen activator reduces neurological damage after cerebral embolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

The validity of rodent brain-ischemia models is self-evident

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.97

21 January 2018

Identifiers

DOI

10.1517/14728214.12.1.97

1 reference

25 July 2017

1 reference

PubMed ID

17355216